Panoptes Pharma Ges.m.b.H., a new biopharmaceutical company founded in Vienna, Austria, has announced the successful closing of its seed funding investment round of EUR1.2M. The… Read More »Panoptes Pharma raises first investment for novel chronic uveitis treatment
Ophthotech Corporation (Princeton, New Jersey) has announced that is has filed its intention with the US Securities and Exchange Commission (SEC) for an initial public… Read More »Ophthotech Corporation aims to raise over $100M in IPO on NASDAQ
ThromboGenics NV (Euronext: THR) suffered a share price fall of just over 30% following announcement of the company’s 6-monthly US sales data on the recently… Read More »ThromboGenics share price falls on announcement of 2013H1 sales of Jetrea (ocriplasmin)
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) confirmed on August 6th the completion of its acquisition of Bausch & Lomb Holdings Incorporated for… Read More »Valeant Pharmaceuticals completes acquisition of Bausch & Lomb for $8.7 billion
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced that EYLEA (aflibercept) injection has been recommended for approval by the European Committee for Medicinal Products for Human… Read More »Regeneron increases market reach for Eylea drug following expansion of labelling by European Medicines Agency
iCo Therapeutics Inc (TSX-V: ICO), headquartered in Vancouver, Canada has announced completion of enrolment in the Phase II “iDEAL” study designed to evaluate the efficacy… Read More »iCo Therapeutics announces enrolment completion and clinical update on Phase II iDEAL study for the treatment of diabetic macular edema (DME)
ThromboGenics NV and Novartis AG have announced the launch of Jetrea ocriplasmin in Denmark and Sweden for the treatment of vitreomacular traction including when associated… Read More »ThromboGenics announces launch of Jetrea in Denmark and Sweden for treatment of vitreomacular traction
Ophthotech Corporation (Princeton, New Jersey) has announced the execution of an agreement with Novo A/S valued at $175M. The deal is set to fund the… Read More »Ophthotech Corporation receives $175M to progress a Phase III clinical trial for Fovista
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) has announced the acquisition of Bausch & Lomb Holdings Incorporated for a reported $8.7 billion in cash.… Read More »Valeant announce deal to acquire Bausch & Lomb for $8.7 billion
Allergan Inc. (NYSE:AGN) showed a drop in their share value at the beginning of May following disclosure in their 1Q13 earnings of a 1-2 year… Read More »Allergan Inc., announces a delay of up to 2-years for its AMD pipeline